BG63744B1 - Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания - Google Patents

Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания Download PDF

Info

Publication number: BG63744B1
Authority: BG; Bulgaria
Prior art keywords: propyl; acid; compound; hexic; migraine
Prior art date: 1998-06-22

Application number

BG105163A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG105163A (bg

Inventor

Heinz Nau

Emer Leahy

Alan O'connell

Original Assignee

American Biogenetic Sciences, Inc.

Heinz Nau

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-22

Filing date

2001-01-17

Publication date

2002-11-29

2001-01-17 Application filed by American Biogenetic Sciences, Inc., Heinz Nau filed Critical American Biogenetic Sciences, Inc.

2002-03-29 Publication of BG105163A publication Critical patent/BG105163A/xx

2002-11-29 Publication of BG63744B1 publication Critical patent/BG63744B1/bg

Links

208000019695 Migraine disease Diseases 0.000 title claims abstract description 37
238000011282 treatment Methods 0.000 title claims abstract description 22
206010027599 migraine Diseases 0.000 title claims abstract description 11
230000002265 prevention Effects 0.000 title claims abstract description 10
NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical class CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title abstract description 21
150000001875 compounds Chemical class 0.000 claims abstract description 40
239000002253 acid Substances 0.000 claims abstract description 36
238000000034 method Methods 0.000 claims abstract description 30
239000008194 pharmaceutical composition Substances 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
208000017194 Affective disease Diseases 0.000 claims description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
206010026749 Mania Diseases 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims description 4
208000020925 Bipolar disease Diseases 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 3
238000007920 subcutaneous administration Methods 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
238000004090 dissolution Methods 0.000 claims description 2
239000003182 parenteral nutrition solution Substances 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims 1
238000001990 intravenous administration Methods 0.000 claims 1
239000006186 oral dosage form Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 40
229940079593 drug Drugs 0.000 abstract description 35
239000003814 drug Substances 0.000 abstract description 35
230000002829 reductive effect Effects 0.000 abstract description 12
230000002460 anti-migrenic effect Effects 0.000 abstract description 3
206010029350 Neurotoxicity Diseases 0.000 abstract description 2
206010044221 Toxic encephalopathy Diseases 0.000 abstract description 2
231100000228 neurotoxicity Toxicity 0.000 abstract description 2
230000007135 neurotoxicity Effects 0.000 abstract description 2
VWPXMGURRCAAAR-UHFFFAOYSA-N 2-propylhex-3-ynoic acid Chemical compound CCCC(C(O)=O)C#CCC VWPXMGURRCAAAR-UHFFFAOYSA-N 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 description 38
210000004727 amygdala Anatomy 0.000 description 24
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical class [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 24
229960000604 valproic acid Drugs 0.000 description 19
241000700159 Rattus Species 0.000 description 18
238000012360 testing method Methods 0.000 description 18
208000019022 Mood disease Diseases 0.000 description 16
238000002474 experimental method Methods 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 12
206010003591 Ataxia Diseases 0.000 description 10
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 10
229940102566 valproate Drugs 0.000 description 10
230000002757 inflammatory effect Effects 0.000 description 9
239000001961 anticonvulsive agent Substances 0.000 description 8
206010015037 epilepsy Diseases 0.000 description 8
230000004044 response Effects 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
238000000692 Student's t-test Methods 0.000 description 7
230000036760 body temperature Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000012353 t test Methods 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
238000007912 intraperitoneal administration Methods 0.000 description 6
230000033001 locomotion Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
230000000573 anti-seizure effect Effects 0.000 description 5
230000007423 decrease Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
206010019233 Headaches Diseases 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000003390 teratogenic effect Effects 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
208000000060 Migraine with aura Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229960003965 antiepileptics Drugs 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000002964 excitative effect Effects 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
-1 gums Chemical compound 0.000 description 3
231100000869 headache Toxicity 0.000 description 3
230000002197 limbic effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
206010052787 migraine without aura Diseases 0.000 description 3
230000007971 neurological deficit Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
231100000378 teratogenic Toxicity 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 2
102100034033 Alpha-adducin Human genes 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
208000033001 Complex partial seizures Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
101000799076 Homo sapiens Alpha-adducin Proteins 0.000 description 2
206010021118 Hypotonia Diseases 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
101000629598 Rattus norvegicus Sterol regulatory element-binding protein 1 Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
206010043275 Teratogenicity Diseases 0.000 description 2
208000001407 Vascular Headaches Diseases 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
230000003556 anti-epileptic effect Effects 0.000 description 2
229940125681 anticonvulsant agent Drugs 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229960000623 carbamazepine Drugs 0.000 description 2
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229960001903 ergotamine tartrate Drugs 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000036640 muscle relaxation Effects 0.000 description 2
238000002559 palpation Methods 0.000 description 2
230000001314 paroxysmal effect Effects 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229940032147 starch Drugs 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
231100000211 teratogenicity Toxicity 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
206010053398 Clonic convulsion Diseases 0.000 description 1
206010009346 Clonus Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
206010020400 Hostility Diseases 0.000 description 1
208000000269 Hyperkinesis Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000006240 Linum usitatissimum Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000008457 Neurologic Manifestations Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010061334 Partial seizures Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
206010054956 Phonophobia Diseases 0.000 description 1
206010034960 Photophobia Diseases 0.000 description 1
LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
208000012886 Vertigo Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
210000003489 abdominal muscle Anatomy 0.000 description 1
239000003522 acrylic cement Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
229940125684 antimigraine agent Drugs 0.000 description 1
229940124433 antimigraine drug Drugs 0.000 description 1
230000006399 behavior Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000005978 brain dysfunction Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229940075960 desitin Drugs 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000003255 drug test Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960004943 ergotamine Drugs 0.000 description 1
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
238000010304 firing Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
208000018883 loss of balance Diseases 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000010339 medical test Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000007510 mood change Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008289 pathophysiological mechanism Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000001603 reducing effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000015227 regulation of liquid surface tension Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
238000013112 stability test Methods 0.000 description 1
235000000891 standard diet Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
231100000889 vertigo Toxicity 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG105163A 1998-06-22 2001-01-17 Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания BG63744B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9028198P	1998-06-22	1998-06-22
PCT/US1999/014081 WO1999066920A1 (en)	1998-06-22	1999-06-22	The use of valproic acid analog for the treatment and prevention of migraine and affective illness

Publications (2)

Publication Number	Publication Date
BG105163A BG105163A (bg)	2002-03-29
BG63744B1 true BG63744B1 (bg)	2002-11-29

Family

ID=22222101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105163A BG63744B1 (bg)	1998-06-22	2001-01-17	Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания

Country Status (19)

Country	Link
US (2)	US6268396B1 (cs)
EP (1)	EP1089725A1 (cs)
JP (1)	JP2002518442A (cs)
KR (1)	KR20010071572A (cs)
CN (1)	CN1310622A (cs)
AU (2)	AU752192B2 (cs)
BG (1)	BG63744B1 (cs)
BR (1)	BR9911421A (cs)
CA (1)	CA2335641A1 (cs)
CZ (1)	CZ20004833A3 (cs)
HU (1)	HUP0102456A3 (cs)
IL (1)	IL140415A0 (cs)
MX (1)	MXPA00012808A (cs)
NO (1)	NO20006506L (cs)
PL (1)	PL345364A1 (cs)
SK (1)	SK19992000A3 (cs)
TR (2)	TR200003800T2 (cs)
WO (1)	WO1999066920A1 (cs)
ZA (1)	ZA200007652B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6104802A (en)	1997-02-10	2000-08-15	Genesys Telecommunications Laboratories, Inc.	In-band signaling for routing
DE60013811T2 (de) *	1999-05-04	2005-11-17	Keith R. Edwards	Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen
US6555585B2 (en) *	2000-07-21	2003-04-29	Teva Pharmaceutical Industries, Ltd.	Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
DK1311256T3 (da) *	2000-08-17	2005-11-28	Teva Pharma	Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
US20020103110A1 (en) *	2001-01-26	2002-08-01	Spitzer A. Robert	System and method for rectal administration of medication for treatment of migraines
US7968569B2 (en) *	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2004037843A2 (en) *	2002-10-25	2004-05-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
WO2004050084A2 (en) *	2002-11-29	2004-06-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Ace-inhibitors having antioxidant and nitricoxid-donor activity
AU2003289782A1 (en) *	2002-12-16	2004-07-09	The University Of British Columbia	Valproic acid analogues and pharmaceutical compositions thereof
EP1543831A1 (en) *	2003-12-18	2005-06-22	Pfizer GmbH Arzneimittelwerk Gödecke	Pregabalin composition
US20060025477A1 (en) *	2004-07-22	2006-02-02	Artman Linda D	Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
EP1928807A4 (en) *	2005-09-02	2011-05-04	Picobella Llc	ONCOGENIC REGULATORS RNA FOR DIAGNOSIS AND THERAPY
US7459280B2 (en) *	2006-02-27	2008-12-02	Picobella, Llc	Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) *	2007-04-26	2008-10-30	Friedrich-Alexander University Of Erlangen-Nuremberg	Combined immunological agent and sensitizing agent for the treatment of cancer
AU2013257710B2 (en) *	2012-05-08	2016-10-20	Cellixbio Private Limited	Compositions and methods for the treatment of neurological disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2442M (fr)	1962-10-17	1964-04-06	Henry Eugene	L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central.
US3701729A (en)	1970-06-01	1972-10-31	Tenneco Chem	Oil-soluble mixed copper soap products
US3847956A (en)	1973-04-06	1974-11-12	Us Agriculture	2-hydroperoxycarboxylic acids and their preparation
US3932285A (en)	1973-10-03	1976-01-13	Tenneco Chemicals, Inc.	Chromium salt compositions and a process for their production
US4025649A (en)	1974-08-19	1977-05-24	Labaz	Acetic acid derivatives having pharmacological activity and compositions containing the same
US4129599A (en)	1975-04-28	1978-12-12	The Board Of Trustees Of Leland Stanford Jr. University	A-Norsteroids
JPS5680116A (en)	1979-12-05	1981-07-01	Sanyo Electric Co Ltd	Manufacture of substrate for magnetic bubble
JPH0233704B2 (ja)	1982-10-07	1990-07-30	Takeda Chemical Industries Ltd	Chikanbinirukarubonsanjudotai
FR2599737B1 (fr)	1986-06-10	1989-05-19	Sanofi Sa	Procede pour la fixation de groupes alkyles, alkenyles, cycloalkyles ou aralkyles sur une chaine carbonee portant un groupement fonctionnel
JPH01135740A (ja)	1987-11-24	1989-05-29	Nippon Mining Co Ltd	光学活性を有する２―アルキル―１―アルカン酸の製造方法
US5021398A (en)	1989-10-26	1991-06-04	Amp Incorporated	Method of forming patterned oxide superconducting films
US5102913A (en) *	1991-07-01	1992-04-07	Halikas James A	Treatment for cocaine use employing valproic acid
DE4231085A1 (de) *	1992-09-12	1994-03-17	Desitin Arzneimittel Gmbh	VPA-analoge Antiepileptika
EP0661993B1 (en)	1992-09-16	1997-05-07	Genentech, Inc.	Protection against liver damage by hgf
DE69313298T2 (de)	1992-11-30	1998-03-26	Procter & Gamble	Hochschäumende waschmittelzusammensetzungen mit speziell ausgewählten seifen
JP3304459B2 (ja)	1992-12-18	2002-07-22	松下電器産業株式会社	電解コンデンサ駆動用電解液およびそれを用いた電解コンデンサ
EP0632008B1 (en)	1993-06-01	1998-02-04	Ono Pharmaceutical Co., Ltd.	Pentanoic acid derivatives
US5503830A (en)	1993-09-10	1996-04-02	Petrovax, L.L.C.	Compounds having immunostimulating activity and methods of use thereof
WO1995033044A1 (en)	1994-05-27	1995-12-07	The Procter & Gamble Company	Liquid laundry detergent compositions comprising specially selected soaps
US5681854A (en)	1995-11-22	1997-10-28	Alcon Laboratories, Inc.	Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
IT1283489B1 (it)	1996-07-23	1998-04-21	Chiesi Farma Spa	Ammidi di alfa-amminoacidi,loro preparazione e loro impiego terapeutico

1999
- 1999-06-22 PL PL99345364A patent/PL345364A1/xx not_active Application Discontinuation
- 1999-06-22 SK SK1999-2000A patent/SK19992000A3/sk unknown
- 1999-06-22 MX MXPA00012808A patent/MXPA00012808A/es unknown
- 1999-06-22 IL IL14041599A patent/IL140415A0/xx unknown
- 1999-06-22 US US09/337,986 patent/US6268396B1/en not_active Expired - Fee Related
- 1999-06-22 CA CA002335641A patent/CA2335641A1/en not_active Abandoned
- 1999-06-22 HU HU0102456A patent/HUP0102456A3/hu unknown
- 1999-06-22 JP JP2000555606A patent/JP2002518442A/ja active Pending
- 1999-06-22 EP EP99930555A patent/EP1089725A1/en not_active Withdrawn
- 1999-06-22 BR BR9911421-6A patent/BR9911421A/pt not_active IP Right Cessation
- 1999-06-22 WO PCT/US1999/014081 patent/WO1999066920A1/en not_active Ceased
- 1999-06-22 TR TR2000/03800T patent/TR200003800T2/xx unknown
- 1999-06-22 CZ CZ20004833A patent/CZ20004833A3/cs unknown
- 1999-06-22 AU AU47071/99A patent/AU752192B2/en not_active Ceased
- 1999-06-22 CN CN99808955A patent/CN1310622A/zh active Pending
- 1999-06-22 KR KR1020007014630A patent/KR20010071572A/ko not_active Withdrawn
- 1999-06-27 TR TR2001/03249T patent/TR200103249T2/xx unknown
- 1999-06-28 AU AU52071/99A patent/AU5207199A/en not_active Abandoned
2000
- 2000-12-19 ZA ZA200007652A patent/ZA200007652B/en unknown
- 2000-12-20 NO NO20006506A patent/NO20006506L/no not_active Application Discontinuation
2001
- 2001-01-17 BG BG105163A patent/BG63744B1/bg unknown
- 2001-04-23 US US09/840,376 patent/US6458840B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1089725A1 (en)	2001-04-11
CA2335641A1 (en)	1999-12-29
WO1999066920A1 (en)	1999-12-29
US20010031789A1 (en)	2001-10-18
AU752192B2 (en)	2002-09-12
NO20006506D0 (no)	2000-12-20
CN1310622A (zh)	2001-08-29
NO20006506L (no)	2001-02-21
AU5207199A (en)	2000-01-24
KR20010071572A (ko)	2001-07-28
MXPA00012808A (es)	2002-04-24
BG105163A (bg)	2002-03-29
IL140415A0 (en)	2002-02-10
AU4707199A (en)	2000-01-10
HUP0102456A3 (en)	2003-07-28
TR200103249T2 (tr)	2002-05-21
TR200003800T2 (tr)	2001-06-21
CZ20004833A3 (cs)	2002-01-16
BR9911421A (pt)	2001-03-27
HUP0102456A2 (hu)	2001-10-28
US6458840B2 (en)	2002-10-01
PL345364A1 (en)	2001-12-17
JP2002518442A (ja)	2002-06-25
US6268396B1 (en)	2001-07-31
SK19992000A3 (sk)	2001-08-06
ZA200007652B (en)	2002-03-19

Publication	Publication Date	Title
JP3693258B2 (ja)	2005-09-07	イソブチルｇａｂａまたはその誘導体を含有する鎮静剤
CA2498260C (en)	2014-02-04	Pharmaceutical formulations of modafinil
KR100785182B1 (ko)	2007-12-11	수면 장애를 위한 가바펜틴 유사체
US20020058656A1 (en)	2002-05-16	Triple drug therapy for the treatment and prevention of acute or chronic pain
US20040029941A1 (en)	2004-02-12	Zonisamide use in obesity and eating disorders
HUP0303983A2 (hu)	2004-04-28	Peptidvegyületek új alkalmazása az allodynia vagy más krónikus vagy fantom típusú fájdalom kezelésére
AU2008220668A1 (en)	2008-09-04	Treatment of anxiety disorders with minocycline
CA2586975A1 (en)	2006-05-18	Method for treatment of movement disorders
CZ297284B6 (cs)	2006-10-11	Farmaceutiký prostredek pro lécbu syndromu neklidných nohou
HUE033180T2 (en)	2017-11-28	Peptide compounds for the treatment of difficult to cure epileptic diseases
JP2014221797A (ja)	2014-11-27	トラマドール及びセレコキシブを含む疼痛治療用組成物
RU2166318C2 (ru)	2001-05-10	Флюпиртин - действующее вещество медицинских и фармакологических средств с активностью антагониста эксайторных аминокислот
CN1141937C (zh)	2004-03-17	含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物
US6268396B1 (en)	2001-07-31	Use of valproic acid analog for the treatment and prevention of migraine and affective illness
EA019354B1 (ru)	2014-03-31	Применение димирацетама для лечения хронической боли
CN111328282A (zh)	2020-06-23	加波沙朵在治疗发作性睡病中的用途
ES2390225T3 (es)	2012-11-07	Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión
MXPA06015196A (es)	2007-03-15	Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide.
US7915262B2 (en)	2011-03-29	Combination preparations comprising SLV308 and a dopamine agonist
CA2134783C (en)	2002-08-13	Use of remacemide for the treatment of parkinson's disease
TW200528098A (en)	2005-09-01	Treatment of insomnia in human patients
JP5042425B2 (ja)	2012-10-03	機能性胃腸疾患治療用トラマドール
EP2035002A1 (en)	2009-03-18	Combination preparations comprising slv308 and a l-dopa
CN118286197A (zh)	2024-07-05	瑞替加滨与（+）-冰片的组合物在抗癫痫中的应用
EP2891491A1 (en)	2015-07-08	Use of (r)-phenylpiracetam for the treatment of sleep disorders